CTI BioPharma Corp.

3.04-0.0100-0.33%Vol 452.56K1Y Perf 194.66%
Sep 24th, 2021 16:00 DELAYED
BID3.03 ASK3.04
Open3.07 Previous Close3.05
Pre-Market- After-Market3.04
 - -  - -%
Target Price
6.18 
Analyst Rating
— 0.00
Potential %
103.29 
Finscreener Ranking
★★★+     51.09
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     48.39
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     45.02
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
65.18 
Earnings Rating
Sell
Market Cap283.66M 
Earnings Date
9th Nov 2021
Alpha0.01 Standard Deviation0.25
Beta0.77 

Today's Price Range

3.023.07

52W Range

1.004.13

5 Year PE Ratio Range

-1.30-2.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-0.33%
1 Month
9.35%
3 Months
29.91%
6 Months
8.57%
1 Year
194.66%
3 Years
40.74%
5 Years
-20.00%
10 Years
-93.98%

TickerPriceChg.Chg.%
CTIC3.04-0.0100-0.33
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
4.60
4.70
0.02
0.06
-74.20
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-1 885.30
-1 861.90
-551.90
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-54.98
-37.25
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.20-0.21-5.00
Q01 2021-0.20-0.23-15.00
Q04 2020-0.16-0.20-25.00
Q03 2020--0.15-
Q02 2020--0.19-
Q01 2020--0.20-
Q04 2019--0.14-
Q03 2019--0.17-
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.22-10.00Negative
12/2021 QR0.01103.45Positive
12/2021 FY-0.6529.35Positive
12/2022 FY-0.57-21.28Negative
Next Report Date9th Nov 2021
Estimated EPS Next Report-0.22
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume452.56K
Shares Outstanding93.31M
Shares Float71.27M
Trades Count3.32K
Dollar Volume2.21M
Avg. Volume815.41K
Avg. Weekly Volume514.87K
Avg. Monthly Volume857.23K
Avg. Quarterly Volume738.54K

CTI BioPharma Corp. (NASDAQ: CTIC) stock closed at 3.04 per share at the end of the most recent trading day (a -0.33% change compared to the prior day closing price) with a volume of 453.64K shares and market capitalization of 283.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. CTI BioPharma Corp. CEO is Adam R. Craig.

The one-year performance of CTI BioPharma Corp. stock is 194.66%, while year-to-date (YTD) performance is -5.59%. CTIC stock has a five-year performance of -20%. Its 52-week range is between 1 and 4.13, which gives CTIC stock a 52-week price range ratio of 65.18%

CTI BioPharma Corp. currently has a PE ratio of -3.90, a price-to-book (PB) ratio of 4.61, a price-to-sale (PS) ratio of 33.81, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -79.94%, a ROC of -98.02% and a ROE of -103.86%. The company’s profit margin is -%, its EBITDA margin is -1 861.90%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from CTI BioPharma Corp., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. CTI BioPharma Corp.’s next earnings report date is 09th Nov 2021.

The consensus rating of Wall Street analysts for CTI BioPharma Corp. is (0), with a target price of $6.18, which is +103.29% compared to the current price. The earnings rating for CTI BioPharma Corp. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CTI BioPharma Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CTI BioPharma Corp. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.42, ATR14 : 0.10, CCI20 : -14.59, Chaikin Money Flow : 0.00, MACD : 0.08, Money Flow Index : 38.32, ROC : -0.65, RSI : 58.12, STOCH (14,3) : 25.00, STOCH RSI : 0.47, UO : 46.16, Williams %R : -75.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CTI BioPharma Corp. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Strong Buy
1.00

CTI BioPharma Corp.

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. The company's therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CEO: Adam R. Craig

Telephone: +1 206 282-7100

Address: 3101 Western Avenue, Seattle 98121, WA, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

52%48%

TipRanks News for CTIC

Mon, 30 Aug 2021 16:38 GMT CTI BioPharma (CTIC) Gets a Buy Rating from BTIG

- TipRanks. All rights reserved.

Fri, 06 Aug 2021 09:55 GMT CTI BioPharma (CTIC) Receives a Buy from Needham

- TipRanks. All rights reserved.

Fri, 06 Aug 2021 03:45 GMT Analysts Offer Insights on Healthcare Companies: CTI BioPharma (CTIC) and BellRing Brands (BRBR)

- TipRanks. All rights reserved.

News

Stocktwits